Compare UTG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTG | MLYS |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | UTG | MLYS |
|---|---|---|
| Price | $37.08 | $36.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.40 |
| AVG Volume (30 Days) | 317.8K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.86 | N/A |
| Revenue | ★ $96,107,593.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.20 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $25.26 | $8.24 |
| 52 Week High | $35.29 | $47.65 |
| Indicator | UTG | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 37.94 |
| Support Level | $37.04 | $37.61 |
| Resistance Level | $38.00 | $44.13 |
| Average True Range (ATR) | 0.71 | 2.05 |
| MACD | 0.06 | -0.71 |
| Stochastic Oscillator | 46.75 | 2.72 |
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.